Roger Nolan, PhD: Chief Executive Officer
linkedin
Dr. Roger Nolan joined the Plakous Therapeutics team in February 2018. Dr. Nolan has 30+ years’ experience in managing drug and biologic development
programs in start-up companies, including preclinical, clinical and regulatory strategy, and management of consultant and strategic partner interactions. He most recently served as President and co-founder of Biokier, Inc.

Dr. Nolan received his PhD in Biochemistry and Pharmacology from the University of Melbourne.

Scott Washburn, MD: Founder, President, and Medical Director
linkedin
Dr. Washburn joined the Department of Ob/Gyn at Wake Forest University School of Medicine in 1990. While there, he was a co-investigator for several seminal trials of Menopausal Hormone Replacement Therapy. Additionally, his research with colleagues in the Department of Comparative Medicine led to six patents granted for a selective estrogen receptor modulator. Upon leaving Wake Forest to join Lyndhurst Gynecologic Associates, Dr. Washburn has continued to practice Obstetric and Gynecologic surgery. The adverse effects of adhesions on both surgical complications and long term surgical success are a daily battle in his practice. The clinical potential of birth-tissue-based therapeutics led Dr. Washburn to co-found Birth Tissue Recovery, Inc. in 2013. Plakous Therapeutics is an independent entity spun out of Birth Tissue Recovery in the spring of 2016.

Scott is a named inventor on numerous patents and has published over fifteen peer-reviewed articles.

Seth Tomblyn, PhD: Co-founder and Chief Science Officer
linkedin
In 2011, Dr. Tomblyn joined KeraNetics, an early-stage life sciences company that spun out of Wake Forest Baptist Medical Center.  He served as Principal and Co-Investigator on multiple contracts and grants from the Department of Defense and National Institutes of Health, where he collaborated with researchers from many prestigious government and academic research institutions.  Dr. Tomblyn has broad experience in protein and cellular therapies with government, academic, and industrial research facilities.  He has worked extensively on the development of biomaterials for the delivery of drugs, growth factors, and cells to regenerate musculoskeletal tissue and skin.  Dr. Tomblyn received his Bachelors degree in Chemistry and Biology from Fairmont State University, his Doctorate in Microbiology and Molecular Medicine from Clemson University, and was a Postdoctoral Fellow at Case Western Reserve University, Department of Biomedical Engineering.

Seth is a co-inventor on several pending patents and has published over a dozen articles in numerous peer-reviewed journals.

The human villous placenta synthesizes, stores and distributes a remarkable spectrum of chemokines that orchestrate the development of a single cell into a fully functional human in the approximate 270-day interval between conception and delivery.